Business context and reporting period
Precision Optics Corporation, Inc. designs and manufactures optical components, medical imaging systems, and related products, serving medical-device, defense/aerospace, and industrial markets. This Form 10-Q covers the quarter and nine months ended March 31, 2024—the company’s fiscal 2024 third quarter, notwithstanding the request metadata’s “2023 Q3” label.
Financial performance
| Metric | Three months ended March 31, 2024 | Three months ended March 31, 2023 | Nine months ended March 31, 2024 | Nine months ended March 31, 2023 |
|---|---|---|---|---|
| Revenue | $5.243 million | $5.048 million | $14.388 million | $16.020 million |
| Gross profit / margin | $1.859 million / 35.5% | $1.736 million / 34.4% | $4.773 million / 33.2% | $5.975 million / 37.3% |
| Operating loss | $0.259 million | $0.493 million | $1.368 million | $0.024 million |
| Net loss | $0.317 million | $0.398 million | $1.540 million | $0.048 million |
| Basic and diluted loss per share | $0.05 | $0.07 | $0.25 | $0.01 |
- Quarterly revenue grew 3.9%; nine-month revenue fell 10.2%. Quarterly engineering-design revenue rose 62.4%, while optical components fell 7.9% and finished products and assemblies fell 45.5%.
- For the nine-month period, engineering-design revenue increased 35.7%, but optical components declined 19.9% and finished products and assemblies declined 41.3%. The prior-year period included $600,000 of one-time technology-rights revenue.
- Operating cash flow was a use of $1.707 million for the nine months, versus a source of $0.526 million in the prior-year period. Investing activities used $0.282 million; financing activities used $0.012 million. Cash declined $2.001 million to $0.925 million from June 30, 2023.
- At March 31, 2024, current assets were $8.391 million and current liabilities $5.126 million; working capital was approximately $3.264 million. Cash was $0.925 million, accounts receivable $4.224 million, and inventory $3.032 million.
- Debt included $2.340 million of principal on term loans and $0.400 million drawn on the revolving credit line. The revolver had $0.850 million available, subject to its borrowing base. The term loans are secured by company assets and include a minimum debt-service coverage covenant.
Changes, outlook, and risks
- Management attributed lower component sales to reduced customer orders as customers rebalance inventories accumulated amid earlier supply-chain concerns. Lower finished-product sales reflected timing between mature program exits, ongoing-product reorders, and new program introductions.
- Management expects development engagements to progress toward production orders and describes an expanding customer project pipeline, including opportunities in single-use medical devices and defense/aerospace. The filing provides no quantified revenue, earnings, or cash-flow guidance.
- Nine-month gross margin fell to 33.2% from 37.3%; management noted that the prior-year $600,000 technology-rights sale had no associated cost of sales. Excluding that item, prior-year nine-month gross margin would have been 34.9%.
- Liquidity is a key concern: cash fell substantially, operating cash flow was negative, and the company drew $0.400 million on its revolver. The filing also reports approximately $2.5 million of open purchase-order commitments.
- Other notable items: the doubtful-account allowance rose to $826,434 from $606,715 at June 30, 2023; capital equipment purchases increased, primarily for new computer systems. Management reported no goodwill or patent impairment, no material pending or threatened litigation known to it, and effective disclosure controls and internal control over financial reporting as of March 31, 2024.
Most important facts to verify
- Whether the improvement in quarterly revenue and gross margin can continue despite the nine-month sales decline and weak product-sales categories.
- Customer order patterns, inventory normalization, and timing of new medical and defense/aerospace programs reaching production.
- Cash runway, working-capital requirements, revolver borrowing-base availability, and compliance with loan covenants.
- Receivables collectability and the adequacy of the doubtful-account allowance, as well as the timing and cash impact of the $2.5 million open purchase orders.